View : 210 Download: 0
Comparison of efficacy and safety between third-dose triple and third-dose dual antihypertensive combination therapies in patients with hypertension
- Title
- Comparison of efficacy and safety between third-dose triple and third-dose dual antihypertensive combination therapies in patients with hypertension
- Authors
- Sung K.-C.; Hong S.J.; Rhee M.-Y.; Jeong M.-H.; Kim D.-H.; Lim S.-W.; Park K.; Lee J.B.; Kim S.-Y.; Cho J.-M.; Cho G.-Y.; Heo J.-H.; Kim S.-H.; Lee H.-Y.; Kim W.; Cho D.-K.; Park S.; Shin J.; Pyun W.-B.; Kwon K.; Rha S.-W.; Jung J.-A.
- Ewha Authors
- 권기환; 편욱범
- SCOPUS Author ID
- 권기환; 편욱범
- Issue Date
- 2023
- Journal Title
- Journal of Clinical Hypertension
- ISSN
- 1524-6175
- Citation
- Journal of Clinical Hypertension vol. 25, no. 5, pp. 429 - 439
- Keywords
- combination therapy; hypertension; low-dose
- Publisher
- John Wiley and Sons Inc
- Indexed
- SCIE; SCOPUS
- Document Type
- Article
- Abstract
- We compared the efficacy and safety of third-standard-dose triple and third-standard-dose dual antihypertensive combination therapies in patients with mild to moderate hypertension. This was a phase II multicenter, randomized, double-blind, parallel-group trial. After a 4-week placebo run-in period, 245 participants were randomized to the third-dose triple combination (ALC group; amlodipine 1.67 mg + losartan potassium 16.67 mg + chlorthalidone 4.17 mg) or third-dose dual combination (AL group; amlodipine 1.67 mg + losartan potassium 16.67 mg, LC group; losartan potassium 16.67 mg + chlorthalidone 4.17 mg, AC group; amlodipine 1.67 mg + chlorthalidone 4.17 mg) therapy groups and followed up for 8 weeks. The mean systolic blood pressure (BP) reduction was -18.3 ± 13.2, -13.0 ± 13.3, -16.3 ± 12.4, and -13.8 ± 13.2 mmHg in the ALC, AL, LC, and AC groups, respectively. The ALC group showed significant systolic BP reduction compared to the AL and AC groups at weeks 4 (P =.010 and P =.018, respectively) and 8 (P =.017 and P =.036, respectively). At week 4, the proportion of systolic BP responders was significantly higher in the ALC group (42.6%) than in the AL (22.0%), LC (23.3%), and AC (27.1%) groups (P =.013, P =.021, and P =.045, respectively). At week 8, the proportion of systolic and diastolic BP responders was significantly higher in the ALC group (59.7%) than in the AL (39.3%) and AC (42.4%) groups (P =.022 and P =.049, respectively) at week 8. Third-standard-dose triple antihypertensive combination therapy demonstrated early effective BP control compared to third-standard-dose dual combination therapies, without increasing adverse drug reactions in patients with mild-to-moderate hypertension. © 2023 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC.
- DOI
- 10.1111/jch.14656
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML